# Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

> **NCT00529529** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 805 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Indacaterol 300 μg
- **DRUG:** Salmeterol 50 μg
- **DRUG:** Placebo to indacaterol
- **DRUG:** Placebo to salmeterol

## Key facts

- **NCT ID:** NCT00529529
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 805 (ACTUAL)
- **Last updated:** 2011-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00529529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00529529, "Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00529529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*